Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Travere Therapeutics, Inc. | Financial_Report.xls |
| 10-Q - Travere Therapeutics, Inc. | e610664_10q-retrophin.htm |
| EX-31 - Travere Therapeutics, Inc. | e610664_ex31.htm |
EXHIBIT 32
CERTIFICATION OF
CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report on Form 10-Q of Retrophin, Inc. (f/k/a Desert Gateway, Inc.) (the “Company”), for the quarter ending November 30, 2012 (the “Report”), the undersigned officer of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: March __, 2013
|
RETROPHIN, INC
(f/k/a DESERT GATEWAY, INC.)
|
By:
|
/s/ Martin Shkreli
|
|
|
Chief Executive Officer and
Chief Financial Officer
|